GB Sciences, Inc.
Other OTCTotal Valuation
GB Sciences, Inc. carries a market capitalization of 122,121.00, placing it among publicly traded companies globally. Its enterprise value stands at 3.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 122,121.00 |
| Enterprise Value | 3.62M |
Share Statistics
GB Sciences, Inc. currently has 407.07M shares outstanding.
| Shares Outstanding | 407.07M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 16.74, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 16.74 |
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.28 |
| P/FCF Ratio | -3.21 |
| P/OCF Ratio | -3.21 |
Enterprise Valuation
| EV / Sales | 37.22 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
GB Sciences, Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -33.92, indicating conservative leverage, while an interest coverage ratio of -4.36 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.02 |
| Quick Ratio | 0.00 |
| Debt / Equity | -33.92 |
| Debt / EBITDA | -2.35 |
| Interest Coverage | -4.36 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -863.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
Over the trailing twelve months, GB Sciences, Inc. generated 97,235.00 in revenue and converted that into -1.04M in net income, yielding earnings per share of 0.00. EBITDA reached -848,406.00, while operating income came in at -848,406.00.
| Revenue | 97,235.00 |
| Gross Profit | 97,235.00 |
| Operating Income | -848,406.00 |
| Pretax Income | -1.04M |
| Net Income | -1.04M |
| EBITDA | -848,406.00 |
| EBIT | -848,406.00 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
GB Sciences, Inc. holds 3,016.00 in cash and equivalents against 1.99M in total debt, resulting in a net debt position of 1.99M. Total book value stands at -110.60M, with working capital of -5.32M providing operational flexibility.
| Cash & Cash Equivalents | 3,016.00 |
| Total Debt | 1.99M |
| Net Debt | 1.99M |
| Equity (Book Value) | -110.60M |
| Book Value Per Share | -0.27 |
| Working Capital | -5.32M |
Cash Flow
GB Sciences, Inc. produced -506,443.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -506,443.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -506,443.00 |
| FCF Per Share | 0.00 |
Margins
GB Sciences, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -872.53 and net profit margin of -1,072.60 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -872.53 |
| Pretax Margin | -1,072.60 |
| Profit Margin | -1,072.60 |
| EBITDA Margin | -872.53 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -30.23 |
| FCF Yield | -31.12 |
Stock Splits
GB Sciences, Inc.'s most recent stock split took place on October 31, 2013 with a 10:1 split ratio.
| Last Split Date | 10/31/2013 |
| Split Ratio | 10:1 |
Scores
GB Sciences, Inc. posts an Altman Z-Score of -1,735.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1,735.79 |